ACM
RIGL icon

Altium Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Altium Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-57,103
Closed -$2M – 138
2020
Q4 		$2M Buy
+57,103
New +$1.65M 0.75% 62

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Altium Capital Management's RIGL Position: Q1 2021 in Review

Altium Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q1 2021, closing a stake of 57,103 shares — an estimated $2M sold.

Altium Capital Management first reported a position in RIGL in Q4 2020 and held it in 1 quarter. The position peaked at $2M in Q4 2020. 152 funds tracked by Wall St. Rank hold RIGL as of Q1 2021.

  • Altium Capital Management reported no remaining Rigel Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Altium Capital Management sold 57,103 Rigel Pharmaceuticals shares in Q1 2021, an estimated $2M.
  • Altium Capital Management first reported a position in Rigel Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Altium Capital Management's Rigel Pharmaceuticals position peaked at $2M in Q4 2020.
  • 152 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2021.

Based on Altium Capital Management's 13F filing for Q1 2021, filed 6 May 2021.